A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

Inclusion criteria

• Able and willing to provide a written informed consent；
• Male or female, ≥18 years of age；
• Histologically or cytologically confirmed solid tumors；
• At least 1 bone metastasis demonstrated by radiologic imaging or histopathology；
• Eastern Cooperative Oncology Group performance Status≤2。
• Life expectancy was judged by the investigators to be at least 6 months;
• Adequate organ function at Screening
• Female subjects with a negative blood pregnancy test and are not breastfeeding

Exclusion criteria

• Pre-existing or comorbid related oral diseases or oral cavity requiring surgery, etc；
• History of major joint (e.g., hip, knee, or shoulder) trauma or surgery prior to the first dose of the drug；
• Received radiotherapeutic drugs or bone radiotherapy prior to the first study drug administration
• Any cardiovascular disease for which the investigator considers the subject unfit to participate in the study
• resting tachycardia or resting bradycardia;
• The subject's pain is predominantly from pain unrelated to the bone metastases;
• Subject is unable to perform a pain assessment;
• Symptomatic or treatment-requiring brain metastases or other central nervous system metastases
• Comorbid infectious disease
• Prior receipt of exogenous nerve growth factor or anti-nerve growth factor antibodies;
• Prior history of allergy to relevant drug ingredients or components;
• Participation in other clinical trials within a certain period of time
• Subjects who, in the opinion of the investigator, have any other factors